Literature DB >> 20206973

Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy.

Sara M Falzarano1, Ming Zhou, Adrian V Hernandez, Ayman S Moussa, J Stephen Jones, Cristina Magi-Galluzzi.   

Abstract

OBJECTIVES: To determine whether saturation needle biopsy of the prostate (SBx) can accurately predict prostate cancer (PCA) location in radical prostatectomy (RP) specimens. The success of focal therapy for PCA relies on accurate mapping of cancer before the procedure.
METHODS: A total of 72 patients underwent SBx followed by RP for PCA. The biopsy protocol consisted of traditional sextant, plus additional ≥10 cores. A single pathologist mapped the tumor outline on RP, determined the number of PCA foci, their Gleason score (GS), and stage.
RESULTS: Patients' median age and preoperative serum prostate-specific antigen was 60 years and 5.6 ng/mL, respectively. SBx detected bilateral PCA in 33 and unilateral PCA in 39 men. All cases with bilateral PCA by SBx had bilateral tumor in RP. Only 4 of 39 patients with unilateral positive SBx had unilateral cancer in RP. Twelve potentially clinically significant PCA were missed by SBx in 11 of 35 patients: 2 were GS6 and 10 GS7; 11 were stage pT2 and 1 pT3. When patients with unilateral and bilateral positive SBx were compared with respect to prognostic parameters, biopsy GS (P = .004), number of biopsy cores involved (P <.0001), and highest percentage of core (P = .0005) involved by tumor were significantly higher for patients with bilateral positive biopsy.
CONCLUSIONS: Most (90%) patients with unilateral PCA on SBx had bilateral cancer in RP; of those 31% had clinically significant undiagnosed PCA. A negative SBx does not confirm the absence of cancer in the corresponding side of the gland and cannot be used as single determinant when considering a patient for focal treatment.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20206973     DOI: 10.1016/j.urology.2009.11.067

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

1.  Prostate cancer. Saturation biopsy does not accurately localize tumors.

Authors:  Oliver Sartor
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

2.  Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers.

Authors:  Dmitry Volkin; Baris Turkbey; Anthony N Hoang; Soroush Rais-Bahrami; Nitin Yerram; Annerleim Walton-Diaz; Jeffrey W Nix; Bradford J Wood; Peter L Choyke; Peter A Pinto
Journal:  BJU Int       Date:  2014-10-18       Impact factor: 5.588

Review 3.  Prostate zones and cancer: lost in transition?

Authors:  Amin Ali; Alexander Du Feu; Pedro Oliveira; Ananya Choudhury; Robert G Bristow; Esther Baena
Journal:  Nat Rev Urol       Date:  2021-10-19       Impact factor: 14.432

4.  Endorectal MRI and MR spectroscopic imaging of prostate cancer: developing selection criteria for MR-guided focal therapy.

Authors:  Stephanie T Chang; Antonio C Westphalen; Priyanka Jha; Adam J Jung; Peter R Carroll; John Kurhanewicz; Fergus V Coakley
Journal:  J Magn Reson Imaging       Date:  2013-05-16       Impact factor: 4.813

Review 5.  Prostate focused ultrasound focal therapy--imaging for the future.

Authors:  Olivier Rouvière; Albert Gelet; Sébastien Crouzet; Jean-Yves Chapelon
Journal:  Nat Rev Clin Oncol       Date:  2012-08-21       Impact factor: 66.675

6.  Detection of Significant Prostate Cancer According to Anatomical Areas of Sampling Cores Obtained with Transrectal Systematic 12-Core Biopsy.

Authors:  Hiromoto Tei; Hideaki Miyake; Ken-Ichi Harada; Masato Fujisawa
Journal:  Curr Urol       Date:  2015-07-10

7.  Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology.

Authors:  Martin J Magers; Tianyu Zhan; Aaron M Udager; John T Wei; Scott A Tomlins; Angela J Wu; Lakshmi P Kunju; Madelyn Lew; Felix Y Feng; Daniel A Hamstra; Javed Siddiqui; Arul M Chinnaiyan; Jeffrey S Montgomery; Alon Z Weizer; Todd M Morgan; Brent K Hollenbeck; David C Miller; Ganesh S Palapattu; Hui Jiang; Rohit Mehra
Journal:  Med Oncol       Date:  2015-10-06       Impact factor: 3.064

8.  Focal therapy, differential therapy, and radiation treatment for prostate cancer.

Authors:  Anudh K Jain; Ronald D Ennis
Journal:  Adv Urol       Date:  2012-05-16

Review 9.  Focal low-dose rate brachytherapy for the treatment of prostate cancer.

Authors:  William Y Tong; Gilad Cohen; Yoshiya Yamada
Journal:  Cancer Manag Res       Date:  2013-09-13       Impact factor: 3.989

10.  Low incidence of prostate cancer identified in the transition and anterior zones with transperineal biopsy.

Authors:  Teresa L Danforth; K Kent Chevli; Louis Baumann; Michael Duff
Journal:  Res Rep Urol       Date:  2012-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.